In humans, the loss of function mutation of the SCN9A gene that codes for NaV1.7 is linked to channelopathy-associated insensitivity to pain (CIP), while SCN9A gain of function mutations cause paroxysmal extreme pain disorder and primary erythromelalgia [8,29,30]. This evidence concerns the gene SCN9A and channelopathy.